Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

7.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
7.5K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

8.5K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
8.5K
T Cell Types and Functions01:24

T Cell Types and Functions

1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

3.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long non-coding RNA triplex-dependent regulation of melanoma gene networks.

NAR genomics and bioinformatics·2026
Same author

Elucidation of Proteoforms of Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Captured From a Monoclonal Antibody.

Biotechnology and bioengineering·2025
Same author

Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating distinct downstream signaling.

mAbs·2025
Same author

Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands.

mAbs·2024
Same author

First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region.

Antibody therapeutics·2024
Same author

Site-Specific Conjugation of Native Antibody: Transglutaminase-Mediated Modification of a Conserved Glutamine While Maintaining the Primary Sequence and Core Fc Glycan via Trimming with an Endoglycosidase.

Bioconjugate chemistry·2024

Related Experiment Video

Updated: Oct 4, 2025

Spatial and Temporal Control of T Cell Activation Using a Photoactivatable Agonist
07:48

Spatial and Temporal Control of T Cell Activation Using a Photoactivatable Agonist

Published on: April 25, 2018

6.4K

Light-Controllable Binary Switch Activation of CAR T Cells.

Aya Kobayashi1,2,3, Alberto Nobili1,2,3,4, Steven C Neier1,2,3,5

  • 1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Chemmedchem
|February 11, 2022
PubMed
Summary

Researchers developed a novel small molecule-based system to control chimeric antigen receptor (CAR) T cell therapy. This light-sensitive system enhances tumor targeting and reduces side effects, improving CAR T cell therapy safety and efficacy.

Keywords:
Cage compoundsCancerFluorescenceImmunologyPhotolysis

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Related Experiment Videos

Last Updated: Oct 4, 2025

Spatial and Temporal Control of T Cell Activation Using a Photoactivatable Agonist
07:48

Spatial and Temporal Control of T Cell Activation Using a Photoactivatable Agonist

Published on: April 25, 2018

6.4K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Area of Science:

  • Immunology
  • Biotechnology
  • Cancer Therapy

Background:

  • Chimeric antigen receptor (CAR) T cell therapies face challenges like uncontrolled immune activity, off-tumor toxicities, and tumor heterogeneity.
  • Current CAR T cell therapies lack precise control over immune cell activity and tumor targeting.
  • Developing strategies for enhanced control and specificity is crucial for improving CAR T cell therapy's therapeutic index.

Purpose of the Study:

  • To engineer a controllable CAR T cell system using small molecules for enhanced specificity and safety.
  • To demonstrate the ability to redirect CAR T cells to different tumor antigens using small molecule-antibody conjugates.
  • To investigate the use of a light-sensitive system for temporal and spatial control of CAR T cell activation.

Main Methods:

  • Engineered CARs that recognize small molecules instead of direct tumor antigens.
  • Conjugated small molecules to distinct tumor-targeting antibodies for antigen redirection.
  • Utilized ultraviolet light-sensitive caging to control small molecule availability and CAR T cell activation.
  • Assessed CAR T cell-mediated killing in response to light-induced uncaging of small molecules.

Main Results:

  • Small molecule-specific CAR T cells were successfully redirected to target distinct tumor antigens.
  • The system demonstrated binary control over CAR T cell activity, enabling simultaneous targeting of multiple antigens.
  • Ultraviolet light-sensitive caging effectively blocked CAR T cell activation until light exposure.
  • Light-induced uncaging restored CAR T cell-mediated tumor cell killing, demonstrating precise control.

Conclusions:

  • A novel small molecule-based CAR T cell system offers enhanced control over immune activity and tumor targeting.
  • The light-sensitive caging mechanism provides an additional layer of safety and specificity for CAR T cell therapies.
  • This approach has the potential to significantly improve the therapeutic index and broaden the applicability of CAR T cell therapies.